Mereo BioPharma Group Shareholders’ Equity Growth & History (MREO)

Mereo BioPharma Group's shareholders’ equity was $40.9M for fiscal 2025.

View full Mereo BioPharma Group company overview

Mereo BioPharma Group annual shareholders’ equity history

Mereo BioPharma Group annual shareholders’ equity

Fiscal yearPeriod endedShareholders’ equityChangeGrowth
20252025-12-31$40.9M−$20.1M−32.89%
20242024-12-31$61.0M$10.4M+20.64%
20232023-12-31$50.5M−$865,000−1.68%
20222022-12-31$51.4M−$40.8M−44.25%
20212021-12-31$92.2M

Mereo BioPharma Group shareholders’ equity trends

Between the periods ended 2021-12-31 and 2025-12-31, Mereo BioPharma Group's shareholders’ equity decreased from $92.2M to $40.9M, a change of −$51.3M. The latest reported quarter, Q2 2026, shows $28.7M.

About the metric

What shareholders’ equity means

Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.

Calculation and source

SEC-reported shareholders’ equity

TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Mereo BioPharma Group source filings ↗

Community posts

It’s quiet here.

No posts about MREO yet. Start the conversation.

Write the first post